ImmunityBio Inc risk profile
57 Elevated one input has moved against it
Measured 21 October 2026 from IBRX's filed statements. Recomputed nightly.
57 (Elevated), driven by Cash conversion at 100, over 7 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 60 | Stretched | Volatile | One-year price volatility — 106.7% |
| Operating pressure | 0 | Contained | Stable | Costs outgrowing revenue — -665.4 percentage points |
| Cash conversion | 100 | Acute | Stable | Capital spending against operating cash — -0.01x |
| Leverage and coverage | 35 | Normal | Easing | Interest cover — -3.95x |
| Competitive position | 45 | Elevated | Stable | Operating-margin gap against peers — -237.8 percentage points |
| Concentration | 100 | Acute | Stable | Geographic concentration — 9,951 HHI |
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.